Pina-Camacho, Laura http://orcid.org/0000-0003-1960-6443
Martinez, Kenia
Diaz-Caneja, Covadonga M. http://orcid.org/0000-0001-8538-3175
Mezquida, Gisela
Cuesta, Manuel J.
Moreno, Carmen http://orcid.org/0000-0003-0541-4846
Amoretti, Silvia http://orcid.org/0000-0001-6017-2734
González-Pinto, Ana
Arango, Celso http://orcid.org/0000-0003-3382-4754
Vieta, Eduard
Castro-Fornieles, Josefina http://orcid.org/0000-0003-0632-2687
Lobo, Antonio http://orcid.org/0000-0002-9098-655X
Fraguas, David
Bernardo, Miguel http://orcid.org/0000-0001-8748-6717
Janssen, Joost
Parellada, Mara
Madero, Santiago
Gómez-Ramiro, Marta
Rodriguez-Toscano, Elisa
Santonja, Javier
Zorrilla, Iñaki
González-Ortega, Itxaso
Fayed, Nicolás
Santabárbara, Javier
Berge, Daniel
Toll, Alba
Nacher, Juan
Martí, Gracián García
Sague-Vilavella, Maria
Sanchez-Moreno, Jose
de la Serna, Elena
Baeza, Immaculada
Saiz-Masvidal, Cristina
Contreras, Fernando
González-Blanco, Leticia
Bobes-Bascarán, Teresa
Dompablo, Mónica
Rodriguez-Jimenez, Roberto
Usall, Judith
Butjosa, Anna
Pomarol-Clotet, Edith
Sarró, Salvador
,
Article History
Received: 27 April 2021
Accepted: 10 November 2021
First Online: 11 March 2022
Competing interests
: L.P-C. has received grant support from Fundación Alicia Koplowitz and Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, and has received honoraria or grants unrelated to the present work from Rubió, Rovi and Janssen. C.D-C. holds a Juan Rodés grant from Instituto de Salud Carlos III (JR19/00024), Spanish Ministry of Science and Innovation, and has received honoraria from AbbVie, Sanofi, and Exeltis. C.M. has received grants and served as consultant or advisor from European Union Funds, Fundación Alicia Koplowitz, Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, CIBERSAM, Janssen, Angelini, Servier, Nuvelution, Otsuka, Lundbeck and Esteve. E.V. has received grants and served as consultant, advisor or CME speaker unrelated to the present work for the following entities: AB-Biotics, Abbott, Allergan, Angelini, Dainippon Sumitomo Pharma, Ferrer, Gedeon Richter, Janssen, Lundbeck, Otsuka, Sage, Sanofi-Aventis, Sunovion, and Takeda. C.A. has been a consultant, to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Minerva, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion, and Takeda. D.F. has been a consultant to and/or receiving fees from Angelini, Eisai, IE4Lab, Janssen, Lundbeck, and Otsuka and has received grant support from Fundación Alicia Koplowitz and Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation. M.B. has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of ABBiotics, Adamed, Angelini, Casen Recordati, Janssen-Cilag, Menarini, Rovi and Takeda. M.P. has received grants and served as consultant, advisor or CME speaker unrelated to the present work for the following entities: Servier, Exceltis, Lundbeck, Fundación Alicia Koplowitz, Fundación Familia Alonso, Ministry of Health, and Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation. The remaining authors declare no conflict of interest.